| 0.7745 -0.015 (-1.96%) | 01-30 13:33 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.95 | 1-year : | 1.11 |
| Resists | First : | 0.81 | Second : | 0.95 |
| Pivot price | 0.73  |
|||
| Supports | First : | 0.71 | Second : | 0.65 |
| MAs | MA(5) : | 0.72 |
MA(20) : | 0.73 |
| MA(100) : | 1.23 |
MA(250) : | 0.92 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 55.7 |
D(3) : | 35.9 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 2.34 | Low : | 0.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TNYA ] has closed below upper band by 20.7%. Bollinger Bands are 74.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.81 - 0.82 | 0.82 - 0.82 |
| Low: | 0.69 - 0.69 | 0.69 - 0.7 |
| Close: | 0.78 - 0.79 | 0.79 - 0.8 |
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Thu, 22 Jan 2026
Tenaya Therapeutics (TNYA) Valuation After 2026 Gene Therapy Updates And US$60 Million Capital Raise - Sahm
Tue, 20 Jan 2026
Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026 - Finviz
Tue, 13 Jan 2026
Morgan Stanley reduces PT on Tenaya Therapeutics (TNYA), keeps constructive stance on US small- to mid-cap biotech - MSN
Fri, 09 Jan 2026
Gene therapy trials for inherited heart disease face big 2026 tests - Stock Titan
Sun, 14 Dec 2025
Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed - Yahoo Finance
Fri, 12 Dec 2025
Tenaya Therapeutics Announces Pricing of Public Offering - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 217 (M) |
| Shares Float | 121 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 41.5 (%) |
| Shares Short | 22,730 (K) |
| Shares Short P.Month | 21,340 (K) |
| EPS | -0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -49.5 % |
| Return on Equity (ttm) | -96.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -73 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -1.03 |
| PEG Ratio | 0 |
| Price to Book value | 1.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|